Ligand Pharmaceuticals Incorporated (LGND) Q2 2017 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.19%

Ligand Pharmaceuticals reported a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock saw a slight decline of 0.19%, likely due to the lack of revenue information and guidance. Investors may be cautious as they await more detailed financial insights in future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.67	N/A	+67.08%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their focus on upcoming projects.

Management expressed satisfaction with the EPS results despite not providing revenue figures.

They highlighted ongoing projects and potential future developments.

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.19%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.19%

Key numbers

Management commentary